Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Podcast 43: CDMOs/CMOs: The Movers and Shakers of 2023

As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made.

Key topics: (see Chapter Markers in drop down menu in audio player above) 

  • Baxter (2:11)
  • Samsung Biologics (3:39)
  • Lotte Biologics (5:01)
  • Fujifilm Diosynth Biotechnologies (7:04)
  • Lonza (10:42)
  • Cambrex (13:10)
  • Expansions in peptides, oligonucleotides (15:27)
  • Bachem (15:49)
  • Agilent Technologies (17:01)
  • WuXi STA (17:51)
  • CordenPharma (19:01)
  • Ajinomoto (20:32)
  • Bain’s acquisition of F.I.S. (21:19)
  • eureKING (22:32)
  • New CDMOs enter the market (23:41)
  • Bridgewest Group (23:49)
  • SynCrest (24:27)
  • NewBiologix (25:20)
  • Ascend Gene & Cell Therapies (26:19)

Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show  

You May Also Like

Podcast 44: What’s Trending: Parenteral Drug Development & Manufacturing

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights…

Podcast 42: CDMO/CMO Mid-Year Review: Tracking the Key Moves Thus Far in 2023 

As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an…

Podcast 41: API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains 

The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages…

Podcast 40: The CDMO/CMO Report: Parenteral Drugs 

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain…